Cargando…
Gemtuzumab ozogamicin plus standard induction chemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10477319/ https://www.ncbi.nlm.nih.gov/pubmed/37666807 http://dx.doi.org/10.1038/s41408-023-00910-x |
| _version_ | 1785101127475265536 |
|---|---|
| author | Awada, Hassan Abdelmalek, Mina Cronin, Tara Baron, Jeffrey Kashour, Zakariya Azad, Farhan Faisal, Muhammad Salman Faber, Mark Gravina, Matthew Sung, Pamela J. Green, Steven D. Przespolewski, Amanda Thompson, James E. Griffiths, Elizabeth A. Wang, Eunice S. |
| author_facet | Awada, Hassan Abdelmalek, Mina Cronin, Tara Baron, Jeffrey Kashour, Zakariya Azad, Farhan Faisal, Muhammad Salman Faber, Mark Gravina, Matthew Sung, Pamela J. Green, Steven D. Przespolewski, Amanda Thompson, James E. Griffiths, Elizabeth A. Wang, Eunice S. |
| author_sort | Awada, Hassan |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10477319 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104773192023-09-06 Gemtuzumab ozogamicin plus standard induction chemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia Awada, Hassan Abdelmalek, Mina Cronin, Tara Baron, Jeffrey Kashour, Zakariya Azad, Farhan Faisal, Muhammad Salman Faber, Mark Gravina, Matthew Sung, Pamela J. Green, Steven D. Przespolewski, Amanda Thompson, James E. Griffiths, Elizabeth A. Wang, Eunice S. Blood Cancer J Correspondence Nature Publishing Group UK 2023-09-04 /pmc/articles/PMC10477319/ /pubmed/37666807 http://dx.doi.org/10.1038/s41408-023-00910-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Correspondence Awada, Hassan Abdelmalek, Mina Cronin, Tara Baron, Jeffrey Kashour, Zakariya Azad, Farhan Faisal, Muhammad Salman Faber, Mark Gravina, Matthew Sung, Pamela J. Green, Steven D. Przespolewski, Amanda Thompson, James E. Griffiths, Elizabeth A. Wang, Eunice S. Gemtuzumab ozogamicin plus standard induction chemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia |
| title | Gemtuzumab ozogamicin plus standard induction chemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia |
| title_full | Gemtuzumab ozogamicin plus standard induction chemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia |
| title_fullStr | Gemtuzumab ozogamicin plus standard induction chemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia |
| title_full_unstemmed | Gemtuzumab ozogamicin plus standard induction chemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia |
| title_short | Gemtuzumab ozogamicin plus standard induction chemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia |
| title_sort | gemtuzumab ozogamicin plus standard induction chemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10477319/ https://www.ncbi.nlm.nih.gov/pubmed/37666807 http://dx.doi.org/10.1038/s41408-023-00910-x |
| work_keys_str_mv | AT awadahassan gemtuzumabozogamicinplusstandardinductionchemotherapyimprovesoutcomesofnewlydiagnosedintermediatecytogeneticriskacutemyeloidleukemia AT abdelmalekmina gemtuzumabozogamicinplusstandardinductionchemotherapyimprovesoutcomesofnewlydiagnosedintermediatecytogeneticriskacutemyeloidleukemia AT cronintara gemtuzumabozogamicinplusstandardinductionchemotherapyimprovesoutcomesofnewlydiagnosedintermediatecytogeneticriskacutemyeloidleukemia AT baronjeffrey gemtuzumabozogamicinplusstandardinductionchemotherapyimprovesoutcomesofnewlydiagnosedintermediatecytogeneticriskacutemyeloidleukemia AT kashourzakariya gemtuzumabozogamicinplusstandardinductionchemotherapyimprovesoutcomesofnewlydiagnosedintermediatecytogeneticriskacutemyeloidleukemia AT azadfarhan gemtuzumabozogamicinplusstandardinductionchemotherapyimprovesoutcomesofnewlydiagnosedintermediatecytogeneticriskacutemyeloidleukemia AT faisalmuhammadsalman gemtuzumabozogamicinplusstandardinductionchemotherapyimprovesoutcomesofnewlydiagnosedintermediatecytogeneticriskacutemyeloidleukemia AT fabermark gemtuzumabozogamicinplusstandardinductionchemotherapyimprovesoutcomesofnewlydiagnosedintermediatecytogeneticriskacutemyeloidleukemia AT gravinamatthew gemtuzumabozogamicinplusstandardinductionchemotherapyimprovesoutcomesofnewlydiagnosedintermediatecytogeneticriskacutemyeloidleukemia AT sungpamelaj gemtuzumabozogamicinplusstandardinductionchemotherapyimprovesoutcomesofnewlydiagnosedintermediatecytogeneticriskacutemyeloidleukemia AT greenstevend gemtuzumabozogamicinplusstandardinductionchemotherapyimprovesoutcomesofnewlydiagnosedintermediatecytogeneticriskacutemyeloidleukemia AT przespolewskiamanda gemtuzumabozogamicinplusstandardinductionchemotherapyimprovesoutcomesofnewlydiagnosedintermediatecytogeneticriskacutemyeloidleukemia AT thompsonjamese gemtuzumabozogamicinplusstandardinductionchemotherapyimprovesoutcomesofnewlydiagnosedintermediatecytogeneticriskacutemyeloidleukemia AT griffithselizabetha gemtuzumabozogamicinplusstandardinductionchemotherapyimprovesoutcomesofnewlydiagnosedintermediatecytogeneticriskacutemyeloidleukemia AT wangeunices gemtuzumabozogamicinplusstandardinductionchemotherapyimprovesoutcomesofnewlydiagnosedintermediatecytogeneticriskacutemyeloidleukemia |